Skip to main content

Table 5 The association of statins with VAF

From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Author

Design

N (Control)

Exposure Timing

Outcome (duration)

VAF development

Wanner et al [79]

(4D study)

Placebo-controlled

1255 (636)

Atorvastatin

20 mg/day

Incidence of cardiovascular events (4 years)

NA

Fellstrom et al [78]

(AURORA trial)

Placebo-controlled

2776 (1385)

Rosuvastatin

10 mg/day

Pre

Incidence of VA procedure (3.8 years)

Equivalent risk

(RR 1.10, 95% CI 0.95–1.27, P = 0.19)

Baigent et al [76]

(SHARP trial)

Placebo-controlled

9270 (4620)

Simvastatin

20 mg/day

+ Ezetimibe

10 mg/day

Pre

Incidence of VA occulusive events (5 years)

Unclear

(29.7% vs. 33.5%, RR 0.87, 95% CI 0.75–1.00, P = 0.05)

Herrington et al [75]

(Combined analysis of AURORA & SHARP trial)

Placebo-controlled

1432 (725)

Rosuvastatin 10 mg/day

or

Simvastatin

20 mg/day

+ Ezetimibe

10 mg/day

Pre

Incidence of VA occulusive events (4.5 years)

Equivalent risk

(29.3% vs. 30.5%, RR 0.95, 95% CI 0.85–1.05, P = 0.29)

  1. VAF vascular access failure, VA vascular access, RR relative risk, HR hazard ratio, CI confidential interval, Pre pre-operative period, NA not available, 4D Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis, AURORA A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events, SHARP The Study of Heart and Renal Protection